• Advances in disease biology and pathophysiology

  • AL amyloidosis

  • CAR T cell sand other cellular therapies

  • Therapy for non-transplant eligible patients

  • Guidelines in specific clinical situations

  • Immunotherapy / Bispecific antibodies, Antibody drug conjugates, etc.

  • Mensural residual disease and disease assessment

  • Ongoing clinical trials and future trials

  • Options for refractory myeloma – sequencing of therapy in refractory disease

  • Outcome prediction and risk assessment

  • Smoldering myeloma, MGUS and precursor conditions

  • Treatment guidelines for young and fit patients

  • Small molecules and preliminary data

  • Waldenstrom macroglobulinemia